()
 
 

Overview

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology has promise for treating several others diseases including MS, ALS, Huntington's disease and stroke.


Contact Information

110 East 59th Street
New York, NY 10022

tel: 212-557-9000
fax: 212-581-8958


,  



Investor Relations


Management
tel:
fax:
e-mail:




Stock

Exchange: OTCBB
Industry: Diagnostic Substances
Market Cap: $15.7M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.